Le Witt P A, Calne D B
J Neural Transm. 1981;51(1-2):175-84. doi: 10.1007/BF01664014.
We have treated 102 Parkinson patients with bromocriptine for up to 6 years; most of these posed problems of management when referred to us. Forty-two continue to take bromocriptine, at a mean dose of 49 mg daily (range 10-160), in combination with some 50% of their previous optimal dose of levodopa (with or without a decarboxylase inhibitor). We consider the main indications for bromocriptine are severe dyskinesia, early morning dystonia, and "wearing off" reactions. Contraindications include hallucinations, delusions, substantial confusion, acute myocardial infarction, active peptic ulceration, and active pleuropulmonary disease.
我们用溴隐亭治疗了102例帕金森病患者，治疗时间长达6年；这些患者中大多数在转诊到我们这里时都存在管理方面的问题。42例患者继续服用溴隐亭，平均每日剂量为49毫克（范围为10 - 160毫克），同时服用约为之前左旋多巴最佳剂量50%的药物（加或不加脱羧酶抑制剂）。我们认为溴隐亭的主要适应证为严重运动障碍、清晨肌张力障碍和“剂末”反应。禁忌证包括幻觉、妄想、严重意识模糊、急性心肌梗死、活动性消化性溃疡和活动性胸膜肺部疾病。
